261924-66-7

Basic information

• Product Name: 3-Azetidinol, 1-[bis(4-chlorophenyl)methyl]-
• CAS NO: 261924-66-7
• Molecular Formula: C16H15Cl2NO
• Molecular Weight: 308.207
• Mol File: 261924-66-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-Azetidinol, 1-[bis(4-chlorophenyl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Azetidinol, 1-[bis(4-chlorophenyl)methyl]-(261924-66-7)
• EPA Substance Registry System: 3-Azetidinol, 1-[bis(4-chlorophenyl)methyl]-(261924-66-7)

Safety Data

• Hazardous Substances Data: 261924-66-7(Hazardous Substances Data)

Upstream product

• 45347-82-8 azetidine-3-ol 
• 6306-46-3 1-[bromo(4-chlorophenyl)methyl]-4-chlorobenzene 

Downstream Products

• 358970-90-8 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(isoquinol-5-yl)methylsulfonamide 
• 358970-87-3 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(6-ethylpyrid-2-yl)methylsulfonamide 
• 358970-98-6 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(4,6-dimethylpyrimid-2-yl)methylsulfonamide 
• 1161418-93-4 1-[bis(4-chlorophenyl)methyl]azetidin-3-ol tetrafluoroborate 
• 358970-97-5 Drinabant 
• 358971-49-0 1-[bis(4-chlorophenyl)methyl]azetidin-3-yl methanesulphonate 
• 261924-65-6 1-[bis(4-chlorophenyl)methyl]azetidin-3-one 
• 5267-41-4 [bis(4-chlorophenyl)methyl]-amine hydrochloride 

Relevant articles and documents

Heterocycle-substituted 3-alkyl azetidine derivatives

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).